How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Buy
60
ACAD Quote, Financials, Valuation and Earnings
Last price:
$25.13
Seasonality move
:
9.69%
Day range:
$25.06 - $25.77
52-week range:
$13.40 - $28.35
Dividend yield:
0%
P/E ratio:
16.17x
P/S ratio:
4.04x
P/B ratio:
4.64x
Volume:
1.2M
Avg. volume:
1.3M
1-year change:
34.46%
Market cap:
$4.3B
Revenue:
$957.8M
EPS (TTM):
$1.55
Analysts' Opinion
-
Consensus RatingACADIA Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 9 Buy ratings, 6 Hold ratings, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $31.05, ACADIA Pharmaceuticals, Inc. has an estimated upside of 23.57% from its current price of $25.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $17.00 representing 32.35% downside risk from its current price of $25.13.
Fair Value
-
According to the consensus of 16 analysts, ACADIA Pharmaceuticals, Inc. has 23.57% upside to fair value with a price target of $31.05 per share.
ACAD vs. S&P 500
-
Over the past 5 trading days, ACADIA Pharmaceuticals, Inc. has underperformed the S&P 500 by -6.69% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
ACADIA Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ACADIA Pharmaceuticals, Inc. has grown year-over-year revenues for 12 quarters straight. In the most recent quarter ACADIA Pharmaceuticals, Inc. reported revenues of $278.6M.
Earnings Growth
-
ACADIA Pharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter ACADIA Pharmaceuticals, Inc. reported earnings per share of $0.42.
Enterprise value:
3.5B
EV / Invested capital:
--
Price / LTM sales:
4.04x
EV / EBIT:
36.64x
EV / Revenue:
3.30x
PEG ratio (5yr expected):
0.16x
EV / Free cash flow:
34.95x
Price / Operating cash flow:
42.76x
Enterprise value / EBITDA:
31.90x
Gross Profit (TTM):
$962.5M
Return On Assets:
22.31%
Net Income Margin (TTM):
24.94%
Return On Equity:
34.23%
Return On Invested Capital:
31.98%
Operating Margin:
12.83%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $631.9M | $929.2M | $1B | $250.4M | $278.6M | |
| Gross Profit | $605.7M | $851.3M | $962.5M | $231.5M | $257M | |
| Operating Income | -$154.4M | $112.2M | $94.4M | $31.6M | $35.8M | |
| EBITDA | -$149.9M | $124.5M | $108.5M | $34.2M | $38.7M | |
| Diluted EPS | -$0.91 | $0.77 | $1.55 | $0.20 | $0.42 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $640.9M | $521.6M | $499.2M | $788.3M | $1.1B | |
| Total Assets | $717.7M | $602.5M | $632.5M | $976.9M | $1.3B | |
| Current Liabilities | $88.2M | $116.6M | $209.6M | $343.9M | $356.6M | |
| Total Liabilities | $150.7M | $176.8M | $270.4M | $399.7M | $413.5M | |
| Total Equity | $567M | $425.7M | $362.2M | $577.2M | $917.3M | |
| Total Debt | $65.8M | $53.8M | $48.1M | $40.4M | $43M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$92.5M | $202.7M | $198.9M | $63.2M | $74.3M | |
| Cash From Investing | $14.6M | -$153M | -$124.5M | -$82.5M | -$79.4M | |
| Cash From Financing | $21.3M | $10.3M | $29.2M | $268K | $9.4M | |
| Free Cash Flow | -$132.6M | $202.7M | $99M | $63.2M | $73.9M | |
ACAD
Sector
Market Cap
$4.3B
$24.3M
Price % of 52-Week High
88.64%
49.95%
Dividend Yield
0%
0%
Shareholder Yield
-0.79%
-1.67%
1-Year Price Total Return
34.46%
-21.37%
Beta (5-Year)
0.679
0.484
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$26.33
200-day SMA
Buy
Level
$22.81
Bollinger Bands (100)
Buy
Level
21.99 - 26.63
Chaikin Money Flow
Buy
Level
23.9M
20-day SMA
Sell
Level
$26.51
Relative Strength Index (RSI14)
Sell
Level
38.45
ADX Line
Sell
Level
16.61
Williams %R
Buy
Level
-97.4545
50-day SMA
Sell
Level
$26.21
MACD (12, 26)
Sell
Level
-0.15
25-day Aroon Oscillator
Sell
Level
-96
On Balance Volume
Neutral
Level
264.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.0256)
Buy
CA Score
(Annual)
Level (0.7808)
Sell
Beneish M-Score
(Annual)
Level (-1.8682)
Buy
Momentum Score
Level (9)
Buy
Ohlson Score
Level (-3.0532)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.
Stock Forecast FAQ
In the current month, ACAD has received 9 Buy ratings 6 Hold ratings, and 1 Sell ratings. The ACAD average analyst price target in the past 3 months is $31.05.
-
Where Will ACADIA Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that ACADIA Pharmaceuticals, Inc. share price will rise to $31.05 per share over the next 12 months.
-
What Do Analysts Say About ACADIA Pharmaceuticals, Inc.?
Analysts are divided on their view about ACADIA Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ACADIA Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is ACADIA Pharmaceuticals, Inc.'s Price Target?
The price target for ACADIA Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $31.05 according to 16 Wall Street analysts, 9 of them rate the stock a Buy, 1 rates the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is ACAD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ACADIA Pharmaceuticals, Inc. is a Buy. 9 of 16 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ACAD?
You can purchase shares of ACADIA Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ACADIA Pharmaceuticals, Inc. shares.
-
What Is The ACADIA Pharmaceuticals, Inc. Share Price Today?
ACADIA Pharmaceuticals, Inc. was last trading at $25.13 per share. This represents the most recent stock quote for ACADIA Pharmaceuticals, Inc.. Yesterday, ACADIA Pharmaceuticals, Inc. closed at $25.13 per share.
-
How To Buy ACADIA Pharmaceuticals, Inc. Stock Online?
In order to purchase ACADIA Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ACAD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ACAD
Sector
P/E ratio
16.17x
23.45x
PEG ratio
0.16x
-0.01x
P/B ratio
4.64x
1.80x
Price / LTM sales
4.04x
1.53x
Growth Metrics
ACAD
Sector
Revenue growth
11.28%
4.08%
Earnings growth
113.29%
9.94%
Revenue (5-year growth)
23.08%
6.27%
Earnings forecast
$0.14
-$0.19
Profitability
ACAD
Sector
Profitability FY 2024
$861M
$3M
Return on invested capital
31.98%
-33.25%
Return on assets
22.31%
-29.67%
Return on equity
34.23%
-38.71%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Feb
4
Balance Sheet
ACAD
Sector
Total cash
$847M
$25M
Short term investments
$436.4M
$25M
Total assets
$1.2B
$72.5M
Long term debt
$43M
$2.9M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
60
JNUG alert for Jan 31
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
